TY - JOUR
T1 - Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021
AU - Lutrick, Karen
AU - Rivers, Patrick
AU - Yoo, Young M.
AU - Grant, Lauren
AU - Hollister, James
AU - Jovel, Krystal
AU - Khan, Sana
AU - Lowe, Ashley
AU - Baccam, Zoe
AU - Hanson, Hanna
AU - Olsho, Lauren E.W.
AU - Fowlkes, Ashley
AU - Caban-Martinez, Alberto J.
AU - Porter, Cynthia
AU - Yoon, Sarang
AU - Meece, Jennifer
AU - Gaglani, Manjusha
AU - Burns, Joy
AU - Lamberte, Julie Mayo
AU - Miiro, Flavia Nakayima
AU - Bissonnette, Adam
AU - LeClair, Lindsay
AU - Kutty, Preeta K.
AU - Romine, James K.
AU - Stefanski, Elisha
AU - Edwards, Laura J.
AU - Ellingson, Katherine
AU - Gerald, Joe K.
AU - Bedrick, Edward J.
AU - Madhivanan, Purnima
AU - Krupp, Karl
AU - Gerald, Lynn B.
AU - Thompson, Mark
AU - Burgess, Jefferey L.
N1 - Funding Information:
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha Gaglani reports grants from Janssen for the Janssen-Baylor Scott and White Health (BSWH) Respiratory Syncytial Virus Birth Cohort Non-interventional Severity App study and Pfizer for the Pfizer-BSWH Foundation Grants for Independent Learning – Men B Vaccines in Adolescents and serves as co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society, Texas Chapter of the American Academy of Pediatrics. James K. Romine reports support from the Community Environment & Policy, Mel & Enid Zuckerman College of Public Health, and the University of Arizona for employment as a postdoctoral research associate I. Lynn B. Gerald reports institutional support from the National Institutes of Health, the Robert Wood Johnson Foundation, Patient-Centered Outcomes Research Institute, and the American Lung Association; personal fees from UpToDate and Springer; consulting fees from Nemours Children’s Hospital; and board membership on the Arizona Asthma Coalition and the American Lung Association of Arizona. No other potential conflicts of interest were disclosed.
Publisher Copyright:
© 2021 Department of Health and Human Services. All rights reserved.
PY - 2021
Y1 - 2021
N2 - What is already known about this topic? The Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing SARS-CoV-2 infection in adolescents in randomized placebo-controlled Phase III trials. What is added by this report? A prospective cohort of 243 adolescents aged 12–17 years in Arizona completed weekly SARS-CoV-2 testing by nasal swab for 19 consecutive weeks. Under real-world conditions, vaccine effectiveness of full immunization (completion of the second in a 2-dose series ≥14 days earlier) was 92% against SARS-CoV-2 infections irrespective of symptom status. What are the implications for public health practice? In real-world conditions among adolescents aged 12–17 years, the Pfizer-BioNTech vaccine was highly effective in preventing SARS-CoV-2 infection.
AB - What is already known about this topic? The Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing SARS-CoV-2 infection in adolescents in randomized placebo-controlled Phase III trials. What is added by this report? A prospective cohort of 243 adolescents aged 12–17 years in Arizona completed weekly SARS-CoV-2 testing by nasal swab for 19 consecutive weeks. Under real-world conditions, vaccine effectiveness of full immunization (completion of the second in a 2-dose series ≥14 days earlier) was 92% against SARS-CoV-2 infections irrespective of symptom status. What are the implications for public health practice? In real-world conditions among adolescents aged 12–17 years, the Pfizer-BioNTech vaccine was highly effective in preventing SARS-CoV-2 infection.
UR - http://www.scopus.com/inward/record.url?scp=85123036935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123036935&partnerID=8YFLogxK
U2 - 10.15585/MMWR.MM705152A2
DO - 10.15585/MMWR.MM705152A2
M3 - Article
C2 - 34968373
AN - SCOPUS:85123036935
SN - 0149-2195
VL - 70
SP - 1761
EP - 1765
JO - Morbidity and Mortality Weekly Report
JF - Morbidity and Mortality Weekly Report
IS - 5152
ER -